Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Oct 14, 2019 - Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Sep 23, 2019 - Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
Sep 13, 2019 - Consumer groups and unions want the FTC to block AbbVie's (ABBV +0.4%) $63B acquisition of Allergan (AGN), according to a STAT report.The coalition says the increasingly concentrated nature of the hea
Sep 13, 2019 - Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Sep 11, 2019 - The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.